Worth Asset Management LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 196.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,235 shares of the company

Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a research note on Wednesday.

Merck & Co. stock faced a Dutch injunction affecting Keytruda SC sales in eight European markets on

Q2 revenue reached USD 16.61 billion, up 5.10 percent year over year. Merck & Co. stock costs EUR 12

Tulisokibart reached 72.00 percent HiSCR50 at high dose. Merck stock was last at EUR 124.78 on Octob

Merck & Co. stock holds at USD 141.12 on October 6, 2026, while 27 analysts set a Moderate Buy conse

Shares of Merck & Co., Inc. (NYSE:MRK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-seven ratings firms that are currently covering the stock, MarketBeat reports. Eleven equities research analysts have rated the stock with a hold rating and sixteen

Revenue hit USD 16.61 billion in Q2 2026, up 5.10 percent year over year. Merck & Co. stock costs EU

Merck & Co. stock was trading at USD 140.12 on October 5, 2026, while JPMorgan raised its target to

Park National Corp OH trimmed its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 120,805 shares of the company

Argent Capital Management LLC reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 166,757 shares of the company

Rockland Trust Co. lowered its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 458,433 shares of the company

JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an "overweight" rating in a research report on Monday.

MassMutual Private Wealth & Trust FSB lessened its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 6.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 140,363 shares of the company

Revenue rose 5.10 percent to USD 16.61 billion in the second quarter of 2026. Merck & Co. stock cost